Samenvatting
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The 'omics' era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.
| Originele taal-2 | English |
|---|---|
| Pagina's (van-tot) | 437-454 |
| Aantal pagina's | 18 |
| Tijdschrift | Biomarkers in Medicine |
| Volume | 15 |
| Nummer van het tijdschrift | 6 |
| DOI's | |
| Status | Published - apr 2021 |
Bibliografische nota
Funding Information:This study was financially supported by the Fund for Scientific Research-Flanders (FWO Vlaanderen grants G009514N and G010214N),theFundac¸ãodeAmparoàPesquisadoEstadodeSãoPaulo(FAPESP-FWOgrant18/10953-9),theUniversityHospital of the Vrije Universiteit Brussel–Belgium (Willy Gepts Fonds UZ-Brussel) and the Center for Alternatives to Animal Testing at Johns Hopkins University – USA (grant 2018-13). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.